These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9525737)

  • 1. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.
    Amarante-Mendes GP; McGahon AJ; Nishioka WK; Afar DE; Witte ON; Green DR
    Oncogene; 1998 Mar; 16(11):1383-90. PubMed ID: 9525737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
    Hoover RR; Gerlach MJ; Koh EY; Daley GQ
    Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
    Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of bcl-2 or bcl-XL fails to inhibit apoptosis mediated by a novel retinoid.
    Fontana JA; Sun RJ; Rishi AK; Dawson MI; Ordónez JV; Zhang Y; Tschang SH; Bhalla K; Han Z; Wyche J; Poirer G; Sheikh MS; Shroot B; Reichert U
    Oncol Res; 1998; 10(6):313-24. PubMed ID: 9848102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
    Lothstein L; Savranskaya L; Sweatman TW
    Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr/abl-positive leukaemia cells.
    Riordan FA; Bravery CA; Mengubas K; Ray N; Borthwick NJ; Akbar AN; Hart SM; Hoffbrand AV; Mehta AB; Wickremasinghe RG
    Oncogene; 1998 Mar; 16(12):1533-42. PubMed ID: 9569020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells.
    de Groot RP; Raaijmakers JA; Lammers JW; Koenderman L
    Mol Cell Biol Res Commun; 2000 May; 3(5):299-305. PubMed ID: 10964754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.
    Fang G; Chang BS; Kim CN; Perkins C; Thompson CB; Bhalla KN
    Cancer Res; 1998 Aug; 58(15):3202-8. PubMed ID: 9699642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
    Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block.
    Nishii K; Kabarowski JH; Gibbons DL; Griffiths SD; Titley I; Wiedemann LM; Greaves MF
    Oncogene; 1996 Nov; 13(10):2225-34. PubMed ID: 8950990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
    Brieger A; Boehrer S; Schaaf S; Nowak D; Ruthardt M; Kim SZ; Atadja P; Hoelzer D; Mitrou PS; Weidmann E; Chow KU
    Biochem Pharmacol; 2004 Jul; 68(1):85-93. PubMed ID: 15183120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
    Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Moiraghi B; Bengió R; Larripa IB
    Blood Cells Mol Dis; 2010 Oct; 45(3):192-6. PubMed ID: 20728382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
    Wang Z; Sampath J; Fukuda S; Pelus LM
    Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.